GLP-1's Weekly Pills Pens and Progress 17

Posted on November 16, 2026 by Sally-Anne Turner

We are in an exciting period at the Bodyline Clinic.

In the next month or so, we will be launching our new service aimed at young people in the UK aged between 16 and 17 years old!

The aim? To help late teens or young adults with losing weight with injectable semaglutide (Wegovy), to improve their health and to ensure they do so safely. Of course, we also aim to offer support with Wegovy side effects, keeping weight off and psychological impacts of weight loss. It’s going to be great!

Of course, we are not the only ones noting some interesting changes in how we use GLP-1s. Research is now finding more links between GLP-1 medications and other areas of health care than ever before, making it all the more important for potential patients to know as much as they can about these medications.

So, read on to learn more about the newest research in this area of weight loss with GLP_1s Weekly, Pills, Pens and Progress 17!

Less Weight, Less Ache— Retatrutide’s Double Win for Knees

There is an experimental weight loss drug being developed by Eli Lilly.

Called Retatrutide, the phase 3 clinical trials suggest that this medication can reduce osteoarthritis knee pain, while also helping people lose weight.

The two separate studies involved more than 1,000 adults, and participants on the highest dose of Retatrutide lost, on average, 25% of their body weight. In both studies, around two-thirds of those taking this weight loss treatment reported that the pain they felt in their knees had reduced by a minimum of one-half.

For a quick update, Retatrutide is administered via a weekly injection. Unlike tirzepatide (Mounjaro) that impacts two hormones in the gut, or Wegovy that impacts one, this medication activates three. As a result, the researchers noted a lowering of blood pressure and inflammation in those taking it.

What about the knees and arthritis? Losing weight means that the knees carry less weight, and reducing the pressure on this area has impacts on pain relief. However, it is, at this point, impossible to differentiate between whether the weight loss caused the lack of soreness, or if it was the anti-inflammatory effects of the GLP-1.

As always, this is an area with potential. Could GLP-1s help to reduce arthritis? Or is this an incidental link? At the time of writing, Retatrutide is experimental, and you should not be able to access it anywhere online. So, if you find it on socials, it is fake, and you should report it.

You can read the original study here: https://pubt.io/view/0DADCBE27F52AF38B688B648503EADCECCAC6484

Prediabetic Prevention with GLP-1’s

Prediabetes is, as the name suggests, the clinical term for people who are close to developing type 2 diabetes. So, it should come as no surprise that this group experience an interesting reduction in symptoms when given a GLP-1.

We all know about the link between pre-diabetes and heart health. So, what does it mean when a GLP-1 has more of an impact than a medication like metformin, a medication used to treat diabetes?

Presented at the American Heart Association (AHA) Scientific Sessions 2026, it was found that people who have a diagnosis of obesity and are pre diabetic have been prescribed GLP 1 medications to assess the impact of this medication on heart health. The result? They experienced fewer cardiovascular problems than those prescribed metformin.

The study involved 256000 adults and linked GLP 1 treatments with a 15% lower incidence of heart attacks, 20% fewer strokes and 25% fewer cases of heart failure. The research team also noted 8% fewer cases of atrial fibrillation, which is an irregular heart rhythm. Alongside a 41% lower risk of death from any cause.

With spoken about this before and these findings add intrigue as to why these obesity medications are helping to protect long-term health alongside helping people to lose weight. The study itself cannot determine how much of this apparent benefit came from weight reduction on its own, effects of GLP-1s with other medications, or, of course, the individual differences between the people receiving the treatments. However, the results are intriguing.

A core distinction is that these are preliminary results and, as always, more research is needed. They do not establish that switching from metformin to a GLP-1 will definitively prevent a heart attack or a stroke.

If you want to read the original study, you can check it out here: https://www.ajmc.com/conference/aha.

Want to Start GLP-1s? Research Says Support is Becoming Essential

Let’s start this news segment off with what we have always said. GLP-1 treatments need more than a quick sign-off after a digital consultation.

And now, it seems that point of view is gaining traction. A head nutritionist at ZOE stated at The Economist’s Future of Health Europe event on 3 November that GLP-1 services and providers have focused too heavily on the effectiveness of medications like Wegovy and Mounjaro over other areas, such as maintenance, nutrition, and the physical health of the people taking them.

There has been research that has found weight management medication is often followed by the regaining of weight once that medication stops. A meta-analysis of 37 studies which involve 9,341 adults has found that the average weight regain is around 0.4 kilogrammes per month for GLP-1 medications that have been stopped. With the ever-popular Wegovy vs Mounjaro, the average weight regain was 0.8kg per month.

So, this begs the question that the providers competing over the cost of these treatments need to ask: what happens when those taking these medications don’t get support afterwards?

Indeed, it has been suggested, following these studies, that psychological support is offered, as well as eating-disorder screening and even structured clinical assessments and medication reviews. Notice something? Our team at the Bodyline Clinic offers all of these, and we are one of the few GLP-1 treatment providers who do.

Does this mean other providers will soon follow suit? Who knows! Soon, Mounjaro weight loss may be accompanied with extensive support in all clinics in the UK.

Check out the paper here: https://www.emjreviews.com/general-healthcare/news/glp-1-aftercare-being-neglected-despite-evidential-need-expert-warns

Bodyline, GLP-1s and Support

If you want to undertake GLP-1s, whether you have mental health issues or cardiac issues, you will need support. Even if you don’t need specialised support, undertaking any kind of weight loss medication should not be something that you do after a quick consultation.

At the Bodyline Clinic, our clinical team is able to offer you everything from an initial assessment, through to helping you keep the weight off once you hit your weight loss goals. We know how to define which options may help you with healthy weight loss, while also helping you to manage any co-existing health issues.

Do you need more than a quick consultation when starting weight loss treatment? Contact our team at the Bodyline Clinic today, and let’s start your weight loss journey together.

About The Author

Sally-Anne Turner

I am founder and Managing Director of Bodyline, with over two decades of experience in the healthcare and wellness industries. I combine a deep understanding of medical wellness with a passion for science-backed health solutions and future-focused care. I have a specialist interest in developing gold standard clinical services for medical weight loss, including the latest GLP-1 medications, hormone health, and low-dose naltrexone (LDN) treatments.

Related Treatment News